Physician profile
Mark S Langfitt
NPI 1003876194
$811.00
in general payments reported to CMS, 2019-2025
12 companies · $293 in 2025
The $293 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $36.23 · 2023: $92.36 · 2024: $248 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $167.79 | 2024-2025 | Odactra, Grastek, Neffy |
| Ironshore Pharmaceuticals INC. | $149.35 | 2019-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $121.54 | 2025 | Jornay Pm |
| Pfizer INC. | $100.39 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $64.72 | 2019-2025 | Vaxneuvance, Gardasil 9, Varivax |
| Tris Pharma INC | $61.31 | 2019-2025 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $50.08 | 2019-2024 | Bexsero, Menveo, Rotarix |
| Supernus Pharmaceuticals, INC. | $33.31 | 2024 | Qelbree |
| Sanofi Pasteur INC. | $17.19 | 2019 | |
| Cranial Technologies, INC | $16.88 | 2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $14.49 | 2025 | |
| Shire North American Group INC | $13.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Langfitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.